Menu
$349.00 – $54,400.00
The BinaxNOW COVID-19 Ag Card is a lateral flow immunoassay for the qualitative detection of the nucleocapsid protein antigen to
SARS-CoV-2 directly from anterior nasal (nares) swab specimens.
This Item is not for resale and you must provide a valid CLIA license number in order to purchase it.
The BinaxNOW rapid antigen test is a highly portable, easy-to-use, affordable test that provides results in 15 minutes. The point-of-care Ag card allows testing at scale in CLIA-waived settings, with NAVICA app integration for easy access to results and reporting. NAVICA is a complementary app that pairs with BinaxNOW. This app allows people who test negative to have a temporary encrypted digital pass that displays their results, similar to an airline boarding pass. This allows organizations to verify negative test results—enabling people to move about with greater confidence. Each kit contains 40 individual test devices, ideal for large group settings or high volume testing sites.
In the USA, this product has not been FDA cleared or approved; but has been authorized by the FDA under an Emergency Use Authorization (EUA). This product has been authorized only for the detection of proteins from SARS- CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated, or authorization is revoked sooner.
| Weight | 2 lbs |
|---|---|
| Dimensions | 10 × 8 × 5 in |
| UOM | Case/1 – 640 tests, Kit/1 – 40 tests, Pallet – 8640 tests |
$349.00 – $54,400.00
The BinaxNOW COVID-19 Ag Card is a lateral flow immunoassay for the qualitative detection of the nucleocapsid protein antigen to
SARS-CoV-2 directly from anterior nasal (nares) swab specimens.
This Item is not for resale and you must provide a valid CLIA license number in order to purchase it.
The BinaxNOW rapid antigen test is a highly portable, easy-to-use, affordable test that provides results in 15 minutes. The point-of-care Ag card allows testing at scale in CLIA-waived settings, with NAVICA app integration for easy access to results and reporting. NAVICA is a complementary app that pairs with BinaxNOW. This app allows people who test negative to have a temporary encrypted digital pass that displays their results, similar to an airline boarding pass. This allows organizations to verify negative test results—enabling people to move about with greater confidence. Each kit contains 40 individual test devices, ideal for large group settings or high volume testing sites.
In the USA, this product has not been FDA cleared or approved; but has been authorized by the FDA under an Emergency Use Authorization (EUA). This product has been authorized only for the detection of proteins from SARS- CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated, or authorization is revoked sooner.
| Weight | 2 lbs |
|---|---|
| Dimensions | 10 × 8 × 5 in |
| UOM | Case/1 – 640 tests, Kit/1 – 40 tests, Pallet – 8640 tests |
©2023 360 HEALTH SERVICES | All Rights Reserved.
